Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenoty... (e lipid peroxides and have the potential...)

HOME >> MEDICINE >> TECHNOLOGY

Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing

Date:11/5/2007

e lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may di
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)

Post Your Comments:

(Date:5/19/2013)... , May 19, 2013 The non-surgical ... low temperature radiofrequency (RF) energy is effective in ... or reduces the need for medication 10 years ... presented today at the Digestive Disease Week (DDW) ... Florida . "The sustained ...

(Date:5/18/2013)... The Open Paradigm Project, in collaboration ... Psychiatry , and leading organizations in the movement ... media campaign showcasing video testimonials by individuals negatively ... on pathology and illness rather than wellness and ... Association,s (APA) rollout of its latest revision of ...

(Date:5/17/2013)... , May 17, 2013 The power of ... important ways in which mankind depends on the plant ... Garden,s multifaceted exhibition Wild Medicine: Healing ... on view from May 18 through September 8, ... The featured exhibition,s many attractions include a re-creation ...

Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2 Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3 Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2

[0] Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy [0] New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses [0] Wild Medicine On View at The New York Botanical Garden Through Sept. 8

... FOLD ) today announced that John F. Crowley ... Chairman in order to devote more time to interests related ... role as Executive Chairman, Mr. Crowley will continue to perform ... will advise the current Amicus management team on corporate strategy ...

... The board of directors of Eli Lilly and Company (NYSE: ... second quarter of 2011 of $0.49 a share on outstanding ... 10, 2011 to shareholders of record at the close of ... innovation-driven corporation, is developing a growing portfolio of pharmaceutical products ...

Cached Medicine Technology:Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman 2

Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman Lilly Declares Second-Quarter 2011 Dividend

(Date:5/20/2013)... (PRWEB) May 20, 2013 Along with most ... has remained a fervent proponent of regular oral hygiene, ... and flossing twice a day. While these recommendations are commonplace ... decay reveal that most adults and children are not receiving ... find a new way to break into the practice of ...

(Date:5/20/2013)... Senior Solutions Management Group (SSMG), a ... Southeast, today announced that four of its Resident Assistants ... communities have received The Caring Heart Award from Alzheimer’s ... Loudon, Nicole Braden from River Oaks Place in Loudon, ... and Meghan McCormick from Wellspring Senior Living in Knoxville ...

(Date:5/20/2013)... Texas (PRWEB) May 20, 2013 The main ... market picture for proteomics into a single comprehensive report. ... market shift occurring in this industry. Thus, it is ... , There is also an urgent need in the life ... study the human proteome in a high-throughput, multiplex and low-cost ...

(Date:5/20/2013)... Idol lash has designed its brand new formula ... in a matter of few weeks. It is completely safe ... extra pack offer to help more women achieve broad benefits ... the Idol lash official website. , Numerous trials were conducted ... up to 82% in just a few weeks. According to ...

(Date:5/20/2013)... The Semi Truck Accident Victims ... free service for an innocent victim of a catastrophic ... state our services are unparalleled. What this means is ... victim of a passenger vehicle involved in a semi ... Virginia, Ohio, New Jersey, Indiana, Maryland, Georgia, Nebraska, Kansas, ...

Breaking Medicine News(10 mins):Health News:New AirFloss Product Offers Oral Hygiene Innovation, Dental Professional Warren Melamed Comments 2 Health News:Senior Solutions Management Caregivers Receive Caring Heart Award From Alzheimer’s Tennessee 2 Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 2 Health News:Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com 3 Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2 Health News:Semi Truck Accident Victims Center Urges Family Members Of Victims Injured In A Horrific Semi Truck Accident In Any US State To Call Them First For An Unsurpassed Response 2

[0] New AirFloss Product Offers Oral Hygiene Innovation, Dental Professional Warren Melamed Comments [0] Senior Solutions Management Caregivers Receive Caring Heart Award From Alzheimer’s Tennessee [0] Proteomics Market - Mass Spectrometry & Biochips 2017 Forecast & Analysis in New Research Report at ReportsnReports.com [0] Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com [0] Semi Truck Accident Victims Center Urges Family Members Of Victims Injured In A Horrific Semi Truck Accident In Any US State To Call Them First For An Unsurpassed Response

... ... New York, NY (PRWEB) February 11, 2009 -- What better time ... their health is in their own hands? ZocDoc, the service that ... they have added 40% more cancer screening appointment times this month. ...

... to have compassion for others , , WEDNESDAY, Feb. 11 (HealthDay ... ability to empathize with others, suggests a U.S. study involving ... sound played in a specific cage as negative by also ... cage. But a genetically different strain of mice that were ...

... drug pricing or a ,national health insurance exchange, , , ... of Americans support President Barack Obama,s anticipated overhaul of ... elements as government negotiation with drug companies to lower ... health insurance exchange, a new Harris Interactive/HealthDay ...

... Presented at the Society of Gynecologic Oncologists, 40th Annual ... and ROMA(TM) Over Existing ToolsMALVERN, Pa., Feb. 11 ... at the Society of Gynecologic Oncologists, 40th Annual Meeting ... test - in combination with CA125 blood test results ...

... HCA today announced that it intends to offer ... secured second lien notes due 2017 (the "Notes"). ... offering to repay existing indebtedness, which may include borrowings ... credit facilities. To the extent that proceeds from ...

... ... ------- ... +3.7% EUR7,089m +3.6%, Adjusted net income, excluding selected, ... EUR1,627m +13.9%, Adjusted EPS excluding EUR5.49 +6.2% ...

ZocDoc Joins the Fight Against Cancer Empathy Might Be in the Genes Poll Shows Strong Support for Obama Health Care Reforms Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer HCA Announces Offering of $300 Million Senior Secured Second Lien Notes Sanofi-aventis Delivers 2008 Results Above Guidance

Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...

Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....

Seletz-Gelpi Laminectomy Retractor, self-retaining with arms bent at right angles....

Scoville-Haverfield Hemilaminectomy Retractor...

Medicine Products:

Duet Lumbar Allograft System Graftech Posterior Ramp Seletz-Gelpi Laminectomy Retractor Scoville-Haverfield Hemilaminectomy Retractor